Pfizer fight with Starboard heats up, hedge fund alleges executive pressure
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the U.S. drugmaker to investigate actions by its board, after two former executives backed out of its campaign against the company.
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...
On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...
Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...
The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...
Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback